Central nervous system (CNS) involvement in childhood acute myeloid leukemia (AML) can manifest as leukemic cells in the cerebrospinal fluid, a solid CNS tumor, or as neurological symptoms.
INTRODUCTION
Central nervous system (CNS) is a fairly common site for extramedullary involvement in childhood acute myeloid leukemia M5 morphology) and Inv(16). 1, 2 It has been considered an adverse risk factor associated with a higher risk of relapse. [3] [4] [5] However, other studies on children with AML and CNS involvement have shown either no effect on overall prognosis 1,2 or even better survival in patients with myeloid sarcoma in the CNS. 6 The new pediatric AML protocols have successfully reduced prophylactic CNS irradiation, 7 especially in patients without CNS involvement, and Nordic Society of Pediatric Haematology and Oncology (NOPHO) protocols do not recommend routine CNS irradiation even for patients with CNS involvement.
However, irradiation may be considered in the few cases in which the effect of chemotherapy on CNS disease is unsatisfactory. In this study, we aimed to characterize the presenting clinical features and results of neuroimaging in patients with initial CNS involvement at diagnosis of AML in three Nordic countries (Sweden, Finland, and Denmark). Table 1 . Fifty-eight percent (19/33) of the patients had symptoms related to CNS involvement at diagnosis: visual symptoms including exophthalmos (n = 8), vomiting (n = 6), cranial nerve palsy (facial palsy n = 6, trigeminal nerve symptoms n = 1, abducens nerve palsy n = 1), headache (n = 4), convulsions (n = 3), paresis (n = 3), and irritability (n = 3). In six patients, of whom four had facial palsy, CNS leukemia was diagnosed solely based on symptoms. Fundoscopy was performed in seven patients, of whom four had visual symptoms, showing papilledema in one patient and retinal hemorrhages in another.
RESULTS

Questionnaires
MRI was performed in 13 cases and images were available for central review in nine patients. CT was performed in 14 cases, of which 5 were also investigated by MRI. Imaging was often performed on the day of diagnosis (median time 0 days, range −5 to 27 days). Of the 22 children with imaging, 5 had CNS involvement by imaging, 2 had solid intracranial tumors (Table 2 , patients #1 and #5), 1 had orbital tumor with intracranial contrast enhancement ( Imaging demonstrated intracranial bleeding in three cases (Table   2 , patients #11, #13, and #22) and nonspecific findings assessed as ischemic or toxic encephalopathy in one patient ( Table 2 , patient #7). Of note, seven children had mastoid bone opacification without intracranial abnormalities (three cases detected by MRI, three by CT, and one by both MRI and CT; Table 2 ), which was considered an incidental finding in all cases. All but two patients with mastoid bone opacification had facial palsy. In contrast to the other patients with facial palsy, these two children had clinical signs of sinonasal inflammatory disease (Table 2 , patients #1 and #18).
DISCUSSION
Our study demonstrates that most patients with known CNS involvement, either due to blasts in the CSF or neurological symptoms, had of mastoid opacification. Mastoid cell opacification rates decreased with age ranging from 45% in children younger than 2 years to 6.5%
in adolescents older than 12 years. 14 In our cohort, all but one of the patients with facial palsy and mastoid cell opacification was aged 8 or older.
In this retrospective study, the imaging was not targeted to evaluate the facial nerve, and radiographic resolution may have been too low to detect facial nerve enhancement on MRI, as this was not observed in any of the patients with facial palsy. Furthermore, the radiologist may have paid particular attention to the mastoid cell system in patients with facial palsy and thus noted mastoid cell opacification in the patients with known facial palsy, whereas in other cases it may have not been considered relevant and overlooked. To better clarify the significance of mastoid cell involvement in patients with AML having facial palsy, this observation should be verified in a larger patient series, preferably with thin section contrast-enhanced magnetic resonance scans.
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